Early relapses after the first dose of natalizumab in active multiple sclerosis patients

Multiple Sclerosis

Volumn 14, Issue 8, 2008, Pages 1137-1138

  Centonze, Diego ^a,b   Furlan, R ^c   Gasperini, C ^d   Salvetti, M ^e   Battistini, L ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Monoclonal antibody; Tysabri; VLA 4

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; NATALIZUMAB; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BODY POSTURE; CLINICAL ARTICLE; DIPLOPIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPESTHESIA; LIMB DYSESTHESIA; LIMB WEAKNESS; MALE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; OPTIC NEURITIS; POSTURAL INSTABILITY; RECURRENCE RISK; RELAPSE; SENSORY DYSFUNCTION; UNSPECIFIED SIDE EFFECT; RECURRENT DISEASE; TIME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; RECURRENCE; TIME FACTORS; YOUNG ADULT;

EID: 58149337468     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508092810     Document Type: Article

References (10)

1. Polman, CH, O'Connor, PW, Havrdova, E, et al. AFFIRM investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. Rudick, RA, Stuart, WH, Calabresi, PA, et al. SENTINEL investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
3. Balcer, LJ, Galetta, SL, Calabresi, PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299-1304.
4. Mareckova, H, Havrdova, E, Krasulova, E, Vankova, Z, Koberová, M, Sterzl, I. Natalizumab in the treatment of patients with multiple sclerosis: First experience. Ann N Y Acad Sci 2007; 1110: 465-473.
5. Rudick, RA, Miller, D, Hass, S, et al. AFFIRM and SENTINEL investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335-346.
6. Ransohoff, RM. Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007; 259: 50-52.
7. Vellinga, MM, Castelijns, JA, Barkhof, F, Uitdehaag, BM, Polman, CH. Postwithdrawal rebound increase in t2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150-1151.
8. Calabresi, PA, Giovannoni, G, Confavreux, C, et al. AFFIRM and SENTINEL investigators. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-1403.
9. Humphries, MJ. Monoclonal antibodies as probes of integrin priming and activation. Biochem Soc Trans 2004; 32: 407-411.
10. Hauser, SL, Waubant, E, Arnold, DL, et al. HERMES Trial Group. B-cell depletion with rituximab in relapsingremitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.